This phase IB/II trial is evaluating the safety and effectiveness of using current standard of care treatment in combination with novel targeted therapies to treat metastatic microsatellite-stable colorectal cancer.
This trial is treating patients with Metastatic Microsatellite-stable Colorectal Cancer.
This is a systemic treatment.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer
Commercial Sponsor
MedImmune, LLC
Summary
This study consists of two stages. Stage 1 is a phase 1b trial and will assess the safety of the new treatment regime. Stage 2 is a phase 2 trial which will be assessing the treatment safety and effectiveness. Patients eligible to participate in this study will receive either FOLFOX and bevacuzimab or FOLFOX, bevacuzimab, durvalumab and oleclumab. All treaments will be intravenously administered on Day 1 and 2 of a 14-week cycle.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More